October 22, 2018
1 min read
Save
This article is more than 5 years old. Information may no longer be current.
FDA approves Akorn’s bimatoprost solution
Akorn’s bimatoprost ophthalmic solution 0.03% has received an abbreviated new drug application approval from the FDA to treat hypotrichosis of the eyelashes, according to a press release.
Sales of the solution were approximately $63.5 million between August 2017 and August 2018, the release said.
The solution is indicated to increase the length, thickness and darkness of the eyelashes.